Raloxifene hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for raloxifene hydrochloride and what is the scope of freedom to operate?
Raloxifene hydrochloride
is the generic ingredient in two branded drugs marketed by Lilly, Amneal Pharms, Aurobindo Pharma, Cadila Pharms Ltd, Glenmark Pharms Ltd, Invagen Pharms, Sciegen Pharms Inc, Teva Pharms Usa, and Watson Labs Inc, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.There are seventeen drug master file entries for raloxifene hydrochloride. Eighteen suppliers are listed for this compound.
Summary for raloxifene hydrochloride
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 9 |
NDAs: | 9 |
Drug Master File Entries: | 17 |
Finished Product Suppliers / Packagers: | 18 |
Raw Ingredient (Bulk) Api Vendors: | 117 |
Clinical Trials: | 86 |
Patent Applications: | 6,154 |
What excipients (inactive ingredients) are in raloxifene hydrochloride? | raloxifene hydrochloride excipients list |
DailyMed Link: | raloxifene hydrochloride at DailyMed |
Recent Clinical Trials for raloxifene hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Cairo University | Phase 2 |
German University in Cairo | Phase 2 |
Guangzhou University of Traditional Chinese Medicine | N/A |
Pharmacology for raloxifene hydrochloride
Drug Class | Estrogen Agonist/Antagonist |
Mechanism of Action | Selective Estrogen Receptor Modulators |
Medical Subject Heading (MeSH) Categories for raloxifene hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for raloxifene hydrochloride
US Patents and Regulatory Information for raloxifene hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cadila Pharms Ltd | RALOXIFENE HYDROCHLORIDE | raloxifene hydrochloride | TABLET;ORAL | 211324-001 | Aug 18, 2020 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Glenmark Pharms Ltd | RALOXIFENE HYDROCHLORIDE | raloxifene hydrochloride | TABLET;ORAL | 204491-001 | Mar 22, 2016 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for raloxifene hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | ⤷ Subscribe | ⤷ Subscribe |
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | ⤷ Subscribe | ⤷ Subscribe |
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Raloxifene hydrochloride Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.